The Trump administration will impose tariffs of as much as 100% on certain imported medicines to pressure drugmakers to manufacture more in the US, putting the spotlight back on the major, multinational pharmaceutical industry operating in Ireland. The charges deliver on threats the president made last autumn to impose 100% tariffs on branded or patented medicines unless companies move production to the US. For Irish‑based operations, exposure will depend on how individual firms align their global manufacturing footprints, pricing strategies and future investment plans with US policy. A trade group representing biotech companies criticised the move by the Trump administration. Mr Crowley said the tariffs would create financial risks for smaller biotech companies that often lack the capital to build dedicated manufacturing facilities.
